Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs provides Solid Tumor Targeting CAR-T Development Services via Local-Regional Delivery, designed to overcome poor tumor penetration, systemic toxicity, and long development timelines. Through advanced biomaterial-integrated cell engineering and precision delivery strategies, this next-generation platform enhances CAR-T retention, persistence, and local efficacy within the tumor site while reducing systemic exposure. This approach empowers researchers to accelerate translational development and unlock new therapeutic potential in solid tumor immunotherapy.
By shifting CAR-T administration from systemic infusion to controlled regional or intra-tumoral routes, therapeutic cells bypass biological barriers, including abnormal vasculature and suppressive stromal structures. Literature reports demonstrate improved tumor infiltration and localized immune activation with reduced systemic exposure.
Fig.1 Adjuvant delivery strategies for CAR-T cells in preclinical studies.1
Our service offers a holistic, integrated strategy that moves beyond conventional intravenous (IV) delivery, which is often inefficient for solid tumors. We provide specific deliverables and solutions centered on leveraging local and regional infusion techniques—such as local-regional infusion, biomaterial delivery, and scattered cell seeding—to ensure a higher concentration of active CAR T-cells reaches the target site. This approach is designed to overcome the physical and immunosuppressive barriers of the TME, resulting in superior efficacy and a safer therapeutic profile. This service enables direct or regionally guided CAR-T delivery to the tumor site, improving cellular infiltration, local activation, and anti-tumor potency while minimizing systemic side effects. Our team supports design, optimization, evaluation, and scale-up to match your research or pre-clinical development needs.
Discover How We Can Help - Request a Consultation.
| Strategy Type | Technical Approach | Advantage |
|---|---|---|
| Local Injection |
Direct intra-tumoral injection Intraperitoneal or intracavitary injection |
High local CAR-T concentration with reduced systemic distribution and toxicity |
| Regional Catheter Infusion | Infusion via hepatic artery, pulmonary artery, or cerebral ventricles | Delivers CAR-T directly into the blood supply of solid tumors |
| Implant / Scaffold Systems | CAR-T embedded in microgels, scaffolds, or nanoparticle carriers | Provides local sustained release and protects CAR-T activity |
| Locally Induced Migration | Co-delivery with chemokines or attractant factors | Uses local signals to guide CAR-T accumulation toward the tumor |
| Controlled Release Systems | Hydrogel or microcapsule carriers for sustained CAR-T release | Prolongs local activity and reduces repeated dosing |
Our integrated service covers target and tumor access evaluation to determine optimal delivery routes, customized CAR-T construct design with enhanced persistence traits, regional delivery strategy development for site-specific administration, preclinical efficacy and safety validation using in vivo models, and optimization of dosing regimens and monitoring schemes for clinical translation.
Minimally invasive microneedles deliver CAR-T cells directly into the tumor tissue. This method ensures controlled release, sustained local concentration, and reduced systemic exposure, improving therapeutic efficacy while maintaining safety for accessible or superficial tumors.
A flexible, implantable mesh allows precise localization and retention of CAR-T cells. The micromesh gradually releases cells into surrounding tumor tissue, enhancing infiltration in irregularly shaped or difficult-to-access solid tumors and improving local anti-tumor activity.
CAR-T cells embedded in a biocompatible fibrin matrix are retained locally and released slowly over time. This enhances penetration into dense or fibrotic tumor tissues, supports cell viability, and can be combined with ECM-modulating agents for improved efficacy.
Polymer–nanoparticle hydrogel protects CAR-T cells from mechanical stress and prolongs their activity within the tumor. This controlled delivery improves infiltration, maintains therapeutic concentration, and minimizes systemic distribution, making it suitable for a variety of solid tumor types.
Which tumor types benefit most from bypass trafficking delivery?
Tumors with poor vascular access or dense stromal compartments—such as pancreatic, ovarian, and glioma—commonly benefit.
Can this approach be combined with immune-modulating agents?
Yes, integration with checkpoint inhibitors or cytokine modulators is often effective.
How is dosing determined for regional injection?
Dosing is based on tumor volume, anatomical constraints, and T-cell expansion kinetics.
Are safety concerns different from IV infusion?
Local delivery typically reduces systemic toxicity; however, localized inflammatory responses must be monitored.
With deep CAR-T development experience, state-of-the-art tumor delivery technologies, and clinically informed regional infusion methods, Creative Biolabs enables more efficient tumor-localized activity. Intra-tumoral and regional CAR-T delivery approaches are proven to improve therapeutic response while minimizing systemic immune activation. Creative Biolabs offers comprehensive expertise across CAR-T research, development, and translational evaluation. Reach out to our team to discuss your project and explore tailored solutions.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
